Pomalidomide induced lupus type hypersensitivity reaction

Palumbo, 2011, Multiple myeloma, The New Engl J Medicine, 364, 1046, 10.1056/NEJMra1011442 Tabayashi, 2019, Management of multiple myeloma in the relapsed/refractory patient]. [Rinsho ketsueki], Japan J Clin Hematol, 60, 1257 Roziakova, 2014, Pomalidomide in the treatment of relapsed and refractory multiple myeloma, Klin Onkol, 27, 318, 10.14735/amko2014318 Muz, 2016, Spotlight on ixazomib: potential in the treatment of multiple myeloma, Drug Des Devel Ther., 10, 217 Richardson, 2013, Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib, Blood, 121, 1961, 10.1182/blood-2012-08-450742 Pomalidomide (Rx). Medscape. Retrieved on 11/22/ 2020 from https://reference.medscape.com/drug/pomalyst-pomalidomide-999809#4. Kumar, 2019, NCCN guidelines insights: multiple myeloma, Version 1.2020, J Natl Compr Canc Netw, 17, 1154, 10.6004/jnccn.2019.0049 Oriol, 2020, Limited treatment options in refractory multiple myeloma: promising therapeutic developments, Expert Rev Anticancer Ther, 20, 31, 10.1080/14737140.2020.1708721 Oka, 2019, Successful retreatment with elotuzumab for multiple myeloma with extramedullary relapse while being treated with lenalidomide and dexamethasone, Pathol Oncol Res Tun, 2018, Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma, Blood, 132, 2240, 10.1182/blood-2018-02-835496 Seki, 2017, Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents, Curr Oncol, 24, e328, 10.3747/co.24.3572